Globus Medical Inc. Class A Common Stock vs New York Times Co — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while New York Times Co trades at $66.9 (market cap $10.79B). The key difference: Globus Medical Inc. Class A Common Stock and New York Times Co are close in size by market cap, and New York Times Co pays a 1.38% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and New York Times Co for 82 Days on average.
| GMED | NYT | |
|---|---|---|
Market Cap | $10.25B | $10.79B |
Volume | 1,108,124 | 2,034,872 |
Sector | Health | Media |
52-Week High | $96.82 | $85.86 |
52-Week Low | $58.33 | $54.86 |
Typical Hold Time | 0 Days | 82 Days |
Enterprise Value | $9.76B | $10.18B |
Dividend Yield | — | 1.38% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
The New York Times Company (NYT) trades at $67.15, up 1.62% on the day, with a bearish technical signal but strong fundamental performance. Revenue grew to $2.82 billion in 2025, with net income reaching $344 million and a 12.17% margin. The company has beaten earnings estimates for the last three quarters, and analysts set a consensus price target of $81.50. Recent news includes a dividend declaration and ongoing litigation related to AI copyright issues.
Outlook is mixed: solid earnings growth and profitability support upside, but technical indicators and a shareholder lawsuit pose near-term risks. The stock offers value if it can maintain its growth trajectory, though investors should monitor legal developments and market sentiment closely.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →